Medication info
Cresnon 20 mg (Rosuvastatin Calcium)

Cresnon 20 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/PTP
Approval status
Active

MFDS item code 201003714 · Approved 2010.05.26 · Insurance code 642506250

Summary

Main use
Treatment of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this drug, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. This drug should not be administered to patients with severe renal impairment. Particular caution is required when administering this drug at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. This drug should not be administered to patients with active liver disease. 6. Race : Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goals for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
  • stroke risk
View approved original text

This medication helps patients with primary hypercholesterolemia and mixed hyperlipidemia when dietary control and exercise alone are insufficient. It is also used in conjunction with diet or other therapies to lower blood cholesterol levels in patients with homozygous familial hypercholesterolemia. It reduces total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis and is used as an adjunct therapy in pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. It also assists as a dietary adjunct for patients with primary dysbetalipoproteinemia. Notably, it may reduce the risk of stroke, myocardial infarction, and arterial revascularization in men aged 50 and above and women aged 60 and above who have high-sensitivity C-reactive protein and additional cardiovascular disease risk factors. In summary, this drug is effectively used to lower various forms of hypercholesterolemia and cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Before and during treatment with this drug, patients should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. This drug should not be administered to patients with severe renal impairment. Particular caution is required when administering this drug at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. This drug should not be administered to patients with active liver disease. 6. Race : Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goals for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be used in certain patients. For example, patients who are allergic to this drug, those with severely impaired liver function, muscle disorders, and those taking certain immunosuppressants should not use this medication. Additionally, patients with significantly impaired kidney function and women who are pregnant or breastfeeding should also avoid this drug. This drug can cause muscle problems, so if symptoms like muscle pain or weakness occur, the physician must be notified immediately. Particularly, patients with weakened kidney function or thyroid dysfunction, as well as those who have previously experienced muscle toxic reactions, require extra caution. Since this drug may affect liver function, it is important to undergo regular liver enzyme tests while taking it. Patients who consume alcohol heavily or have a history of liver disease should be especially cautious when utilizing this medication. This medication may elevate blood sugar levels in some patients, so individuals at high risk for diabetes must manage their blood sugar levels effectively. Furthermore, the accumulation of this medication in the body may be higher due to certain genetic factors, which might require dosage adjustment depending on the patient's condition. During the use of this drug, rare but serious side effects such as skin rashes, severe allergic reactions, liver damage, and severe muscle damage may occur; thus, treatment must be halted immediately and consultation with medical personnel is necessary if these symptoms arise. Additionally, this medication may interact with other drugs, so if other medications are being taken, it is essential to inform the physician or pharmacist. Particularly, when used with certain antibiotics, antifungals, immunosuppressants, and fibrate drugs, the risk of muscle toxicity may increase. Pregnant or nursing women should not use this medication, and women who may become pregnant should employ appropriate contraceptive methods. In cases of overdose, there is no specific antidote, so treatment according to symptoms and monitoring of liver and muscle functions are required. Finally, this medication is known not to significantly affect the ability to drive or operate machinery, but caution should be exercised in case of dizziness.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, dysesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue, joint pain, muscle cramps, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 to 30 degrees Celsius. This helps to preserve the drug's effectiveness.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.